It's been more than three decades since India passed a law granting it the authority to grant compulsory licenses over drug patents in case of a public health crisis. On March 13, India finally exercised the powers it granted itself in that law. By granting the domestic Natco Pharma the right to manufacture Bayer's Nexavar cancer-preventative drug, India took precedent setting action that is being watched closely around the world. In this Asian Studies podcast we talk to Matt Schruers, an attorney, Vice-President of Law and Policy at the Computer and Communication Industry Association, and adjunct professor here at Georgetown. Schruers teaches about intellectual property at Georgetown Law and in the Communication Culture and Technology graduate program, he unpacked the legal technicalities of what kind of rights are negotiated with a compulsory license. We also talked to J.P. Singh, a global governance and development scholar, about the history of compulsory licensing in the world and why it took India more than 30 years to order one.